Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months

Posthoc analysis of the RISING study

Tsutomu Takeuchi, Nobuyuki Miyasaka, Takashi Inui, Toshiro Yano, Toru Yoshinari, Tohru Abe, Takao Koike

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective. To investigate the probability of clinical remission (REM) or low disease activity (LDA) after 1 year of infliximab (IFX) therapy based on disease activity at 3 months in patients with rheumatoid arthritis (RA). Methods. Methotrexate-refractory patients with RA received 3 mg/kg of IFX at weeks 0, 2, and 6, followed by 3 mg/kg, 6 mg/kg, or 10 mg/kg every 8 weeks from Week 14 (W14) to Week 46. Correlation of disease activity at W14 with disease activity at W54 and probability of REM/LDA at W54 were analyzed in each dosing group. Results. Disease activities at W14 were significantly correlated with both disease activity at W54 and probability of REM/LDA at W54 in patients continuing 3 mg/kg as well as in those receiving 6 mg/kg or 10 mg/kg therapy from W14. Results showed that, if approximate REM or LDA had not been achieved by W14, ≥ 50% of patients continuing 3 mg/kg therapy would not be able to achieve REMor LDAatW54. However, even in patients with high or moderate disease activity atW14, dose escalation to 6 mg/kg or 10 mg/kg enabled many to achieve REM/LDA. Conclusion. Disease activity at W14 in standard-dose IFX therapy enabled the prediction of longterm clinical response at continued standard dose, as well as subsequent escalated-dose regimens. Disease activity at W14 was hypothesized to be an important index for IFX treatment strategy.

Original languageEnglish
Pages (from-to)599-607
Number of pages9
JournalJournal of Rheumatology
Volume42
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Rheumatoid Arthritis
Therapeutics
Infliximab
Methotrexate

Keywords

  • Clinical response
  • Disease activity
  • Infliximab
  • Prediction
  • Rheumatoid arthritis
  • Rising study

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months : Posthoc analysis of the RISING study. / Takeuchi, Tsutomu; Miyasaka, Nobuyuki; Inui, Takashi; Yano, Toshiro; Yoshinari, Toru; Abe, Tohru; Koike, Takao.

In: Journal of Rheumatology, Vol. 42, No. 4, 01.04.2015, p. 599-607.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Miyasaka, Nobuyuki ; Inui, Takashi ; Yano, Toshiro ; Yoshinari, Toru ; Abe, Tohru ; Koike, Takao. / Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months : Posthoc analysis of the RISING study. In: Journal of Rheumatology. 2015 ; Vol. 42, No. 4. pp. 599-607.
@article{8b4685b20f2843a18b740954f6ffe5bb,
title = "Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: Posthoc analysis of the RISING study",
abstract = "Objective. To investigate the probability of clinical remission (REM) or low disease activity (LDA) after 1 year of infliximab (IFX) therapy based on disease activity at 3 months in patients with rheumatoid arthritis (RA). Methods. Methotrexate-refractory patients with RA received 3 mg/kg of IFX at weeks 0, 2, and 6, followed by 3 mg/kg, 6 mg/kg, or 10 mg/kg every 8 weeks from Week 14 (W14) to Week 46. Correlation of disease activity at W14 with disease activity at W54 and probability of REM/LDA at W54 were analyzed in each dosing group. Results. Disease activities at W14 were significantly correlated with both disease activity at W54 and probability of REM/LDA at W54 in patients continuing 3 mg/kg as well as in those receiving 6 mg/kg or 10 mg/kg therapy from W14. Results showed that, if approximate REM or LDA had not been achieved by W14, ≥ 50{\%} of patients continuing 3 mg/kg therapy would not be able to achieve REMor LDAatW54. However, even in patients with high or moderate disease activity atW14, dose escalation to 6 mg/kg or 10 mg/kg enabled many to achieve REM/LDA. Conclusion. Disease activity at W14 in standard-dose IFX therapy enabled the prediction of longterm clinical response at continued standard dose, as well as subsequent escalated-dose regimens. Disease activity at W14 was hypothesized to be an important index for IFX treatment strategy.",
keywords = "Clinical response, Disease activity, Infliximab, Prediction, Rheumatoid arthritis, Rising study",
author = "Tsutomu Takeuchi and Nobuyuki Miyasaka and Takashi Inui and Toshiro Yano and Toru Yoshinari and Tohru Abe and Takao Koike",
year = "2015",
month = "4",
day = "1",
doi = "10.3899/jrheum.140572",
language = "English",
volume = "42",
pages = "599--607",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months

T2 - Posthoc analysis of the RISING study

AU - Takeuchi, Tsutomu

AU - Miyasaka, Nobuyuki

AU - Inui, Takashi

AU - Yano, Toshiro

AU - Yoshinari, Toru

AU - Abe, Tohru

AU - Koike, Takao

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective. To investigate the probability of clinical remission (REM) or low disease activity (LDA) after 1 year of infliximab (IFX) therapy based on disease activity at 3 months in patients with rheumatoid arthritis (RA). Methods. Methotrexate-refractory patients with RA received 3 mg/kg of IFX at weeks 0, 2, and 6, followed by 3 mg/kg, 6 mg/kg, or 10 mg/kg every 8 weeks from Week 14 (W14) to Week 46. Correlation of disease activity at W14 with disease activity at W54 and probability of REM/LDA at W54 were analyzed in each dosing group. Results. Disease activities at W14 were significantly correlated with both disease activity at W54 and probability of REM/LDA at W54 in patients continuing 3 mg/kg as well as in those receiving 6 mg/kg or 10 mg/kg therapy from W14. Results showed that, if approximate REM or LDA had not been achieved by W14, ≥ 50% of patients continuing 3 mg/kg therapy would not be able to achieve REMor LDAatW54. However, even in patients with high or moderate disease activity atW14, dose escalation to 6 mg/kg or 10 mg/kg enabled many to achieve REM/LDA. Conclusion. Disease activity at W14 in standard-dose IFX therapy enabled the prediction of longterm clinical response at continued standard dose, as well as subsequent escalated-dose regimens. Disease activity at W14 was hypothesized to be an important index for IFX treatment strategy.

AB - Objective. To investigate the probability of clinical remission (REM) or low disease activity (LDA) after 1 year of infliximab (IFX) therapy based on disease activity at 3 months in patients with rheumatoid arthritis (RA). Methods. Methotrexate-refractory patients with RA received 3 mg/kg of IFX at weeks 0, 2, and 6, followed by 3 mg/kg, 6 mg/kg, or 10 mg/kg every 8 weeks from Week 14 (W14) to Week 46. Correlation of disease activity at W14 with disease activity at W54 and probability of REM/LDA at W54 were analyzed in each dosing group. Results. Disease activities at W14 were significantly correlated with both disease activity at W54 and probability of REM/LDA at W54 in patients continuing 3 mg/kg as well as in those receiving 6 mg/kg or 10 mg/kg therapy from W14. Results showed that, if approximate REM or LDA had not been achieved by W14, ≥ 50% of patients continuing 3 mg/kg therapy would not be able to achieve REMor LDAatW54. However, even in patients with high or moderate disease activity atW14, dose escalation to 6 mg/kg or 10 mg/kg enabled many to achieve REM/LDA. Conclusion. Disease activity at W14 in standard-dose IFX therapy enabled the prediction of longterm clinical response at continued standard dose, as well as subsequent escalated-dose regimens. Disease activity at W14 was hypothesized to be an important index for IFX treatment strategy.

KW - Clinical response

KW - Disease activity

KW - Infliximab

KW - Prediction

KW - Rheumatoid arthritis

KW - Rising study

UR - http://www.scopus.com/inward/record.url?scp=84940514659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940514659&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140572

DO - 10.3899/jrheum.140572

M3 - Article

VL - 42

SP - 599

EP - 607

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -